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Abstract
While it has long been understood that CD40 plays a critical role in the etiology of autoimmunity, glycobiology is emerging
as an important contributor. CD40 signaling is also gaining further interest in transplantation and cancer therapies. Work on
CD40 signaling has focused on signaling outcomes and blocking of its ligand, CD154, while little is known about the actual
receptor itself and its control. We demonstrated that CD40 is in fact several receptors occurring as constellations of
differentially glycosylated forms of the protein that can sometimes form hybrid receptors with other proteins. An enticing
area of autoimmunity is differential glycosylation of immune molecules leading to altered signaling. Galectins interact with
carbohydrates on proteins to effect such signaling alterations. Studying autoimmune prone NOD and non-autoimmune
BALB/c mice, here we reveal that in-vivo CD40 signals alter the glycosylation status of non-autoimmune derived CD4 T cells
to resemble that of autoimmune derived CD4 T cells. Galectin-9 interacts with CD40 and, at higher concentrations, prevents
CD40 induced proliferative responses of CD4
loCD40
+ effector T cells and induces cell death through a Tim-3 independent
mechanism. Interestingly, galectin-9, at lower concentrations, alters the surface expression of CD3, CD4, and TCR, regulating
access to those molecules and thereby redirects the inflammatory cytokine phenotype and CD3 induced proliferation of
autoimmune CD4
loCD40
+ T cells. Understanding the dynamics of the CD40 receptor(s) and the impact of glycosylation
status in immunity will gain insight into how to maintain useful CD40 signals while shutting down detrimental ones.
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Introduction
It has long been understood that CD40 – CD154 interactions
are critical in the etiology and perpetuation of autoimmunity and
CD40 is gaining further interest in cancer [1,2,3] and tissue
transplantation [4,5] therapies. CD40 (tnfrsf5) belongs to the
TNF-receptor super family and like other family members it
multimerizes to form the functional receptor [6] which interacts
with its natural ligand CD154. CD40 expression was long
associated only with antigen presenting cells but in actuality its
expression is quite widespread and includes neural [7], endothelial,
epithelial [8], adipocyte [9] and T cells [10,11,12]. We have
identified a CD4
+ subset of T cells that expresses CD40,
CD4
loCD40
+ T cells. Those cells exhibit low surface expression
of CD4, CD3 and TCR but have high levels of those molecules
intracellularly [13]. In the autoimmune model of Type 1 Diabetes
(T1D), the CD4
loCD40
+ T cells expand with progressive insulitis,
prior to overt diabetes, and CD4
loCD40
+ T cells are necessary and
sufficient in transferring disease [11,12,14,15,16].
We recently demonstrated that the CD40 receptor is dynamic,
consisting of different glycoforms of CD40 isoform I and that the
CD40 glycoform profile is different in CD4
loCD40
+ T cells
originating from autoimmune conditions compared to the same
cells from non-autoimmune conditions [17]. A less glycosylated
form of CD40 isoform I is associated with survival and pro-
liferation and CD40 can form hybrid receptors with TNF-
receptors (TNFR) 1 and 2 [17] that are not responsive to TNFa
but are responsive to crosslinking of TNFR1 and/or 2 by means of
antibodies. That crosslinking prevents CD40-induced proliferation
but does not kill the cells [17].
An important discovery was that expansion of the CD4
loCD40
+
T cell subset [14] and diabetes onset [18] in the non-obese diabetic
(NOD) T1D mouse model is prevented by blocking CD40 –
CD154 interaction. This treatment also alters the CD4
loCD40
+ T
cell CD40 glycoform profile to resemble that of non-autoimmune
animals [17]. Conversely, when non-autoimmune BALB/c mice
are CD40 stimulated in-vivo, the CD4
loCD40
+ T cell population is
expanded and the CD40 glycoform profile becomes similar to that
of autoimmune CD4
loCD40
+ T cells [17]. Therefore, while it is
known how to prevent expansion of CD4
loCD40
+ T cells there are
no known mechanisms to control CD4
loCD40
+ T cells once they
are expanded.
Glycosylation impacts immunological functions including cell
trafficking, regulation of TCR activation threshold, and T cell
polarization into Th1, Th2 or Th17 by altering the molecular
interactions of immune molecules at the cell surface [19].
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disease in mice [20,21,22] and autoimmune prone mouse strains,
including NOD, have been shown to express 30–40% less
b1,6GlcNAc-branched N-glycans than non-autoimmune prone
strains [23]. A reduction of GlcNAc-branching by 20–25%
enhances TCR signaling and T cell proliferation [20].
Galectins are a subgroup of lectins that are defined by their
ability to bind b-galactosides in the carbohydrates of glycoproteins
[24]. Several galectins regulate T cell function, for example
galectin-3 interacts with carbohydrates on TCR molecules,
limiting TCR clustering in response to stimulus [22]. In
glycosylation-deficient mice that interaction is disrupted, resulting
in lowered TCR activation threshold [22]. Galectin-3 can also
prevent apoptosis and increase proliferation of T cells [25]. Other
examples include galectin-1 which binds the ganglioside GM-1 in
effector T-cells causing autoimmune suppression [26] and
galectin-9 which attenuates Th1 responses [27] and is protective
against diabetes in the NOD T1D mouse model [28]. It was
shown that galectin-9 exerts its effect on Th1 cells via interaction
with T-cell immunoglobulin and mucin domain-containing pro-
tein 3 (Tim-3) [27], however, it was recently demonstrated that
galectin-9 also regulates T helper function independently of that
molecule [29].
Because galectin-9 controlled Th1 effector cells [27] we
determined whether it could also control the pathogenic
CD4
loCD40
+ T cells in autoimmunity.
Here we demonstrate that galectin-9 can control CD40
signaling in NOD CD4
loCD40
+ T cells, even 24 hours after
signaling was initiated and, if present in higher concentrations, it
induces Tim-3 independent cell death in those cells. We
demonstrate that expanded CD4
loCD40
+ T cells from BALB/c
mice are able to proliferate in response to CD40 signals in-vitro
while non-expanded CD4
loCD40
+ T cells from control BALB/c
mice are not [13]. Galectin-9 also controls CD40 induced
proliferation in those expanded BALB/c CD4
loCD40
+ T cells.
Interestingly, CD40 signals alter the glycosylation status of non-
autoimmune CD4 T cells to appear more like that of autoimmune
CD4 T cells. At lower, sub-lethal concentrations, galectin-9 causes
up-regulation of CD3, CD4, TCR and CD5 on the surface of the
autoimmune CD4
loCD40
+ T cells. The up-regulation of CD3 on
the surface renders the cells more responsive to CD3, increasing
CD3 induced proliferation. Sub-lethal galectin-9 concentrations
also alter the cytokine production by these cells in response to both
CD3 and CD40 signals, decreasing CD40 induced IFNc and IL-6
and increasing CD3 induced IL-2 suggesting that the presence/
absence of galectin-9 may govern the pathogenicity of
CD4
loCD40
+ T cells.
A greater understanding of the dynamics of CD40 and CD3
signaling and the impact of the availability of those molecules for
signaling on the surface of the cells will be imperative in
understanding how to control those cells in autoimmunity.
Results
Galectin-9 prevents CD40 induced survival and
proliferation
Expansion of CD4
loCD40
+ T cells can be prevented by
blocking CD40 – CD154 interactions [14,17]. To date little is
known about how to control CD4
loCD40
+ T cells after they are
expanded and activated. We demonstrated that engagement of
TNFR1 and/or TNFR2 in addition to CD40 prevented CD40
induced proliferation of autoimmune NOD CD4
loCD40
+ T cells
[17] as did Fas engagement [13]. However, those treatments did
not kill the CD4
loCD40
+ T cells. Because galectin-9 has been
shown to induce cell death in Th1 cells [27] we determined
whether it could also affect NOD CD4
loCD40
+ T cells. Galectin-
9 prevented CD40 induced proliferation in a dose dependent
manner (Fig. 1A) and induced necrotic cell death in the CD40
stimulated cells (Fig. 1B; left bar graph). Cells that were isotype
treated for four days underwent necrotic cell death and a large
portion of that was prevented by CD40-stimulation (Fig. 1B;
49.5% and 26.3% cell death respectively). Addition of a lower
concentration, 2.5 mg/ml, of galectin-9 did not prevent the
CD40 induced survival (Fig. 1B; 29% cell death), however, when
higher concentrations were added much of the CD40 induced
survival was prevented. Cell death rates were confirmed with
absolute cell counts in trypan blue (data not shown). Apoptotic
cell death was not apparent in the CD4
loCD40
+ T cells (Fig. 1B;
right bar graph).
In Figure 1B we revealed that galectin-9 added at the time of
CD40 engagement caused the cells to die. We then determined if
galectin-9, added 24 hours after CD40 engagement, could cause
prevention of proliferation and induce cell death despite the fact
that at this point survival/proliferation signals and anti-apoptotic
protein expression are already in operation [13]. Indeed, when
galectin-9 was added to NOD CD4
loCD40
+ T cells 24 hours after
CD40 engagement it stopped most of the proliferation and caused
death of the cells (Fig. 1C).
Considering that galectin-9 was shown to induce Th1 cell death
via ligation of Tim-3 [27], we determined whether galectin-9
suppression of CD40 induced proliferation and galectin-9 induced
cell death in the pathogenic NOD CD4
loCD40
+ T cells could be
attributed to this pathway. Sorted cells were pretreated, or not,
with a Tim-3 blocking antibody then CD40 was stimulated in the
absence/presence of galectin-9. Interestingly, both the galectin-9
suppression of CD40 induced proliferation and the induced cell
death were completely independent of Tim-3 in this pathogenic
CD4 T cell subset (Fig. 1 D and E).
Galectin-9 exerts its proliferation inhibitory and cell
death inducing effects on CD4
loCD40
+ T cells via the
carbohydrate recognition domains of the protein
Galectin-9 consists of two different carbohydrate recognition
domains (CRD) connected to each other with a linker poly-
peptide chain [24]. The interaction of galectin-9 with its
receptors is dependent on the CRD and carbohydrates on the
receptor proteins. Therefore we determined whether the galectin-
9 effects on CD4
loCD40
+ T cells were preventable by lactose,
a competitive substrate that inhibits the interaction of galectins
with their receptors. We have demonstrated previously that
NOD CD4
loCD40
+ T cells form distinct ball shaped clusters
when CD40 engaged [17]. When galectin-9 was added to CD40
engaged NOD CD4
loCD40
+ T cells those clusters no longer
formed (Fig. 2A). However, when lactose was added the cluster
formation was regained. Similarly, when proliferation was
assessed, the galectin-9 inhibition of CD40 induced proliferation
was prevented by the addition of lactose (Fig. 2B, bottom
histogram and 2C). Interestingly, the higher concentration,
30 mM, of lactose inhibited the CD40 induced proliferation
(Fig. 2B, middle histogram and 2C). This could be due to that
other galectins may be involved in survival and proliferative
responses and would be competed for by lactose as well. When
cell death was assessed, 30 mM lactose, but not 10 mM, induced
increased necrotic cell death in the isotype treated and CD40
engaged cells (Fig. 2C) again demonstrating that other galectins
may be involved in survival. When lactose was added to cells
treated with CD40 engagement plus galectin-9, the galectin-9
induced cell death was prevented demonstrating that the CRD of
CD40 and Galectin-9 in Autoaggressive T Cells
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38708Figure 1. Galectin-9 prevents CD40 induced proliferation. (A) CD4
loCD40
+ T cells were sorted from 7–13 week old female NOD spleens and
were then labeled with CFSE. Cells were either isotype treated (Isotype) or CD40 was stimulated (CD40XL) in the absence/presence of increasing
concentrations of galectin-9 (gal-9) for 4 days then CFSE dilution was measured. (B) Cells were sorted and treated as in A and were then stained for
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(Fig. 2C).
In-vivo induced CD4
loCD40
+ T cells from BALB/c mice
acquire the ability to proliferate in response to CD40 in-
vitro and galectin-9 is able to prevent that proliferation
We previously demonstrated that injection of non-autoimmune
BALB/c mice with agonistic CD40 antibodies expanded the
CD4
loCD40
+ T cell population after three to six days to numbers
seen in autoimmune NOD mice [17]. Since that treatment also
altered the CD40 glycoform profile in those cells we determined
whether CD40 signals had an impact on glycosylation status
beyond just the CD40 protein itself in CD4 T cells. The extent
of b1,6GlcNAc-branched N-glycans was assayed using L-PHA,
a plant lectin that binds to carbohydrate structures on
glycoproteins that are also recognized by galectins [23]. Injection
of agonistic CD40 antibodies into non-autoimmune BALB/c
mice caused a reduction in b1,6GlcNAc-branched N-glycans on
CD4
loCD40
+ and CD4
hi T cells to a level similar to that of
autoimmune NOD mice [23] (Fig. 3A; bar graph). This then
could have a direct impact on the activation status of those cells
as has been shown [23]. After fourteen days, the splenic
expansion of CD4
loCD40
+ T cells in the BALB/c mice receded
to normal numbers (unpublished data). Interestingly, in response
to the in-vivo CD40 stimulation, the pancreatic lymph nodes
became populated while in control mice no populated nodes
were found (Fig. 3A; H&E stained images). CD4
loCD40
+ T cells
from control BALB/c mice do not proliferate in response to
CD40 stimulation in-vitro [13]. We determined whether the
expanded CD4
loCD40
+ T cells had acquired the ability to
proliferate in response to CD40 in-vitro in the same manner as
NOD CD4
loCD40
+ T cells do [13] (Fig. 1A). CD4
loCD40
+ T
cells purified three days after a single injection with agonistic
CD40 antibodies readily proliferated in response to CD40
engagement in-vitro (Fig. 3B). However, the expanded BALB/c
CD4
loCD40
+ T cells did not proliferate to the same extent as
NOD CD4
loCD40
+ T cells; 45% of BALB/c CD4
loCD40
+ T
cells proliferated compared to 67.8% of NOD CD4
loCD40
+ T
cells (Fig. 3B). As CD4
loCD40
+ T cells from untreated BALB/c
mice do not proliferate in-vitro in response to CD40 engagement
[13] and since expanded BALB/c CD4
loCD40
+ T cells display
a CD40 glycoform profile similar to NOD CD4
loCD40
+ T cells
[17], the new data indicates that the acquisition of the ‘correct’
CD40 glycoform profile is required before induction of pro-
liferation through CD40 in-vitro is possible.
We determined whether addition of galectin-9 could inhibit the
CD40 induced proliferation of expanded BALB/c CD4
loCD40
+ T
cells. As it did in NOD CD4
loCD40
+ T cells, galectin-9 inhibited
the CD40 induced proliferation of the BALB/c CD4
loCD40
+ T
cells although a lower concentration was sufficient to achieve
complete inhibition of the induced proliferation (Fig. 3C com-
pared to Fig. 1A).
Galectin-9 interacts with CD40
Because galectin-9 had a profound impact on CD40 induced
survival and proliferation of CD4
loCD40
+ T cells we determined
whether galectin-9 could directly interact with CD40. We
performed CD40 co-immunoprecipitation on NOD CD4
loCD40
+
T cell whole cell extracts and separated the resulting proteins on
polyacrylamide gels followed by LC-LC-MS identification. Several
proteins were identified with galectin-9 being one of them (Fig. 4A).
These cells had no exogenously added galectin-9 and therefore the
co-immunoprecipitated galectin-9 represents endogenous galectin-
9. Other proteins of specific interest are VDAC1 (Voltage-
Dependent Anion-selective Channel protein) and VDAC3. CD40
induces high levels of Bcl-XL in NOD CD4
loCD40
+ T cells [13]
and VDAC1 and VDAC3 are proteins found in the mitochondrial
outer membrane where they interact with proteins such as Bcl-XL
to prevent the release of apoptogenic proteins [30]. To corrob-
orate the galectin-9 protein sequencing data we performed CD40
co-immunoprecipitation followed by western blot for galectin-9 on
both NOD and BALB/c CD4
loCD40
+ T cells. While there was
a weak interaction between CD40 and galectin-9 in NOD
CD4
loCD40
+ T cells, that interaction was much stronger in
control BALB/c CD4
loCD40
+ T cells (Fig. 4 B). When in-vivo
expanded BALB/c CD4
loCD40
+ T cells were examined the
interaction was less strong at earlier time points of CD40
engagement but became stronger with longer time (Fig. 4B).
Although the isotype immunoprecipitation did not yield any
galectin-9, since galectins technically could interact with carbohy-
drates on an antibody we performed co-immunoprecipitations
utilizing galectin-9 protein immobilized onto magnetic microbe-
ads. This co-immunoprecipitation strategy revealed CD40 protein
in a western blot (Fig. 4C) demonstrating again that the two
proteins interact directly.
Galectin-9 causes up-regulation of TCR associated
molecules on the surface of autoimmune CD4
loCD40
+ T
cells such that the cells appear similar to conventional
CD4
hiCD3
hi T cells
When culturing CD4
loCD40
+ T cells in the presence of
galectin-9, a change in the morphology was noted. Normally,
when those cells are CD40 engaged distinct ball-shaped clusters
are formed [17] while CD4
hi T cells form more elongated
clusters (Fig. 5A). In the presence of galectin-9 the CD4
loCD40
+
T cells took on a morphology that closely resembled that of
CD4
hi T cells in culture (Fig. 5A). This led us to determine
whether the galectin-9 treated CD4
loCD40
+ T cells also had
a protein surface expression resembling that of CD4
hi T cells.
CD4
loCD40
+ T cells have commonly been discarded or gated
out as non-T cells due to their low surface expression of CD4,
CD3 and TCR but we demonstrated that those cells have high
levels of those proteins intracellularly [13]. NOD CD4
loCD40
+ T
cells were treated with sub-lethal levels, 2 5 mg/ml, of galectin-9
then stained for CD4, CD3, TCR and CD5. Those proteins
were up-regulated on the treated cells as early as two hours after
the treatment (Fig. 5B). A stain for CD8 revealed extremely few,
1–2%, CD8+ cells confirming that the CD4
loCD40
+ T cells
conform to the CD4 lineage.
Phorbol-myristate-acetate activation of CD4 T cells is known to
down regulate the surface expression of CD4 on those cells [31].
CD3 in combination with costimulus of CD28 is a classic way to
necrotic and apoptotic cell death. (C) Cells were sorted and CD40 stimulated as in A for 24 hours then galectin-9 was added at 7.5 mg/ml. Cells were
analyzed for proliferation and cell death after a total of 4 days of stimulation. (D and E) Cells were sorted as in A and were pretreated, or not, with
a Tim-3 blocking antibody (aTim-3) for 30 miutes then CD40 was stimulated in the absence/presence of galectin-9 for 4 days. Proliferation (D) and
cell death (E) was measured, respectively. Percentages in A are means with SEM. Asterisks in B, C, and D denote significant differences determined by
two-way Anova; ns – not significant; * – P between 0.01 and 0.05; ** – P ,0.01; *** – P ,0.001; **** – P,0.0001. Experiments were done at least three
separate times.
doi:10.1371/journal.pone.0038708.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38708Figure 2. Galectin-9 exerts its proliferation inhibitory and cell death inducing effects on CD4
loCD40
+ T cells via the carbohydrate
recognition domains of the protein. CD4
loCD40
+ T cells were sorted from 7–13 week old female NOD spleens and were CFSE labeled. Cells were
either isotype treated (Isotype) or CD40 was stimulated (CD40XL) in the absence/presence of 7.5 mg/ml galectin-9 (gal-9) for 4 days. Lactose was
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can serve a costimulatory role in CD4 T cells [32,33]. Therefore
we examined whether CD4
hi T cells could be activation induced
to appear more like CD4
lo cells in terms of CD4 surface
expression. We determined that sorted CD4
hi T cells from NOD
mice were largely CD28
+ (Fig. 5C) and that although they are
largely CD40
2, a portion of them express low levels of CD40
(Fig. 5C). Interestingly, when CD3 was stimulated together with
both CD28 and CD40 the expression of CD4 on the surface of
those cells was significantly decreased (Fig. 5C).
Galectin-9 renders autoimmune CD4
loCD40
+ T cells
better able to respond to CD3 stimulation
As demonstrated in Figure 5B, galectin-9 at the lower, sub-lethal
concentration, induced higher surface expression of CD3 on
autoimmune CD4
loCD40
+ T cells. We therefore determined
whether this treatment could cause an increase in response to CD3
stimulation of these cells. Untreated CD4
loCD40
+ T cells
spontaneously proliferated over 8 days but when absolute num-
bers of cells were counted it was revealed that they proliferated
and died (Fig. 5D; data not shown). When CD3 was stimulated,
the spontaneous proliferation was tempered (Fig. 5D) and with the
addition of galectin-9, proliferation was increased in response to
CD3 stimulation (Fig. 5D).
Considering the impact of galectin-9 on proliferative responses
of CD4
loCD40
+ T cells to CD3-stimulation we determined
whether galectin-9 could also impact the production of cytokines
by these cells. We determined the level of production of IL-2, IL-
4, IL-5, IL-6, IL-10, IL-17, and IFNc. Regardless of the presence
of galectin-9, the cytokine production was very different
depending on whether CD40 or CD3 was stimulated (Fig. 6
and S1). CD40 induced more IL-6 (Fig. 6) and IL-10 (Fig. S1)
while CD3 induced more IL-17 (more than double the amount
compared to CD40; Fig. S1) and IL-2 (Fig. 6) after 3 days of
stimulation. IFNc production was similar between the two
treatments (Fig. 6). CD40-induced IFNc and IL-6 production
added as a competitor for the CRD of galectin-9. (A) Cell cluster formation was observed. (B) Proliferation was measured by CFSE dilution. (C) Bar
graphs representing proliferation and necrotic cell death. Asterisks in C denote significant differences determined by one-way Anova; ns – not
significant; ** – P between 0.001 and 0.01; *** – P ,0.001; **** – P,0.0001. Data represent experiments done on three individual mice of different
ages.
doi:10.1371/journal.pone.0038708.g002
Figure 3. In-vivo CD40 signals cause non-autoimmune CD4
loCD40
+ T cells to appear more like autoimmune CD4
loCD40
+ T cells. (A)
10–12 week old, female BALB/c mice were injected i.p. with 1C10+FGK45 agonistic CD40 antibodies (CD40-inj.) or with isotype control (control)
antibody. Three days post-injection, splenic CD4
loCD40
+ and CD4
hi T cells were purified and stained with L-PHA. Graph depicts the difference in L-
PHA stain compared to control. Data are represented as means with SEM. Images are H&E stained sections of pancreata. (B) BALB/c mice were treated
and CD4
loCD40
+ T cells purified as in A. CD4
loCD40
+ T cells from 10–12 weeks old female NOD spleens were purified for comparison. Cells were CFSE
labeled then CD40-stimulated for 4 days. CFSE dilution was measured. Dotted line – isotype treated; solid line – CD40-stimunlated. (C) 10 week old
female BALB/c mice were injected and CD4
loCD40
+ T cells purified as in A, then cells were labeled with CFSE and isotype treated (Isotype) or CD40
stimulated (CD40XL) in the absence/presence of galectin-9. CFSE dilution was measured. Percentages in B and C are means +/2 SEM. Experiments
were performed at least three separate times.
doi:10.1371/journal.pone.0038708.g003
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down-regulated in a dose dependent manner (IFNc,P ,0.05; IL-
6, P,0.01). Conversely, CD3 induced IL-2 production was
increased by the addition of galectin-9 (P,0.001). CD40 did not
induce any IL-4 or IL-5 in these cells and while CD3 induced
some, the levels were very low (Fig. S1).
Expression of some cytokines is enhanced when both
CD3 and CD40 are engaged
CD40 has been demonstrated to be a co-stimulatory molecule
on T cells, comparable in its function to CD28 [32]. Therefore we
determined the cytokine production by NOD CD4
loCD40
+ T cells
in response to simultaneous CD3 and CD40 stimulation. IFNc
and IL-2 were induced to significantly higher levels during co-
stimulation compared to single treatment (Fig. 7; note scale
changes compared to Fig. 6). The other cytokine levels were
unaffected by the co-stimulation. Interestingly, while IFNc pro-
duction more than doubled, galectin-9 addition no longer
impacted the level of production. IL-2 production was doubled
by the co-stimulation and remained sensitive to galectin-9 which
increased the induced levels (Fig. 7; note scale changes compared
to Fig. 6).
Discussion
CD40 is known to play a pivotal role in autoimmune disease
and has gained interest as a target in transplantation and cancer
therapies. In autoimmunity the major focus has been on signaling
outcomes, associated signaling molecules, and on preventing its
ligand, CD154, from signaling through CD40. However, little
work has been done focusing on the actual CD40 receptor itself
and how to control it. We recently demonstrated that CD40 is not
one but several dynamic receptors composed of different glyco-
forms of CD40 isoform I and that a less glycosylated form is
associated with survival and proliferation signals [17]. Interesting-
ly, when the receptor(s) is engaged, hybrid receptors can form with
TNFR1 and TNFR2 [17]. Here we reveal a role for CD40 that
could have far-reaching impact on the status of the immune
system. In-vivo, CD40 signaling appears to access glycosylation
events to result in a decrease in b1,6GlcNAc-branched N-glycans
in the CD4 T cell compartment. This could directly affect how
galectins interact with surface glycoproteins and therefore cause
a lowered threshold of activation [23]. Presumably, a network of
cell types in addition to CD4 T cells is involved in this in-vivo
CD40-induced alteration in glycosylation as we were not able to
induce the same change in response to CD40 in-vitro with purified
BALB/c CD4
loCD40
+ T cells (data not shown). If that is the case
this effect on glycosylation events could explain why CD40
appears to have a vast influence on the immune system as a whole
regardless of cell type.
Controlling CD40 signaling has long been an elusive goal in
autoimmunity. All known antibodies to CD40 appear to be
agonistic in nature and blocking its ligand, CD154, is only
successful when administered prior to activation of autoimmune
processes [14,18]. Here we demonstrate that galectin-9 is able to
control culprit CD4
loCD40
+ T cells in T1D not only prior to
CD40 engagement but also after it has induced survival/
proliferation signals. We also demonstrate that higher concentra-
Figure 4. Galectin-9 interacts with CD40. CD4
loCD40
+ T cells were sorted from female NOD, control BALB/c (BALB con.), or agonistic CD40
antibody injected BALB/c (BALB exp.) spleens. Whole cell lysates were prepared. (A) CD40 was immunoprecipitated and resulting proteins were
separated by SDS-PAGE. Protein bands were sequenced by LC-LC-MS. (B) Cells were CD40 stimulated (CD40XL) for 0, 30 minutes, 3 hours or
overnight (09,3 0 9, 3h, o.n.) then lysates were prepared and CD40 immunoprecipitated. Co-imunoprecipitation of galectin-9 was measured in western
blots. Data represents three separate experiments on mice ranging from 8 – 10 weeks old. (C) Cells were isotype or CD40 stimulated (CD40XL)
overnight then lysates were prepared. Galectin-9 protein conjugated directly to magnetic beads was used in immunoprecipitations. Mock treated
beads were used as a control. CD40 was measured in the immunoprecipitated material by western blot. Data represents three separate mice of two
different ages (8 and 10 weeks old).
doi:10.1371/journal.pone.0038708.g004
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38708tions of galectin-9 induce cell death in NOD CD4
loCD40
+ T
cells, suggesting a mechanism to control these pathogenic cells in
autoimmunity. Interestingly, that mechanism is independent of
Tim-3 which has been shown to be involved in galectin-9
induced death of Th1 cells [27]. Instead galectin-9 apparently
exerts its effect on CD4
loCD40
+ T cells via direct interaction
with CD40.
Injection of non-autoimmune BALB/c mice with agonistic
Figure 5. Galectin-9 causes autoimmune CD4
loCD40
+ T cells to appear more like CD4
hi T cells and increases CD3 induced
proliferation. CD4
loCD40
+ and CD4
hi T cells were sorted from 7–13 weeks old female NOD spleens. (A) CD4
loCD40
+ T cells were isotype treated
(Isotype) or CD40-stimulated for 2 days in the absence/presence of indicated concentrations of galectin-9 then photographed under a microscope.
(B) NOD CD4
loCD40
+ T cells were treated for 2 hours with 2.5 mg/ml galectin-9 then stained for CD3, CD4, TCR, CD5 and CD8. Tinted – untreated;
black line – 2.5 mg/ml galectin-9. Gates were set based on appropriate isotype controls. Below each histogram is a corresponding bar graph depicting
the cumulative data. (C) NOD CD4
hi T cells were either stained immediately for CD28 or CD40 (left two histograms; grey tinted – stain-isotype; black
line – CD28 or CD40 as indicated in figure; percentages are means with SEM) or isotype treated or stimulated with CD3+CD28+CD40 overnight then
stained for CD4 (bar graph and right histogram; grey tinted – stain-isotype; black line – isotype treated; dotted line – CD3+CD28+CD40 stimulated).
(D) NOD CD4
loCD40
+ T cells were CFSE labeled then isotype treated (Isotype) or CD3-stimulated (CD3XL) in the absence/presence of indicated
concentrations of galectin-9 (gal-9) for 8 days. Proliferation was measured by CFSE dilution. All bar graphs in this figure depict means with SEM.
Asterisks denote significant differences determined by one- or two-way Anova as appropriate; ns – not significant; * – P between 0.01 and 0.05; ** – P
,0.01; *** – P ,0.001; **** – P,0.0001. Experiments were done at least three separate times.
doi:10.1371/journal.pone.0038708.g005
Figure 6. CD40 and CD3 induced cytokine phenotypes differ
and galectin-9 alters the production level. CD4
loCD40
+ T cells
were sorted from 7–20 weeks old female NOD spleens. Cells were either
isotype treated, CD40- or CD3-stimulated in the absence/presence of
indicated concentrations of galectin-9 (gal-9; mg/ml) for 3 days then
cytokines were measured. Bar graphs depict means with SEM. Asterisks
denote significant differences determined by one-way Anova; * – P
between 0.01 and 0.05; ** – P ,0.01; *** – P ,0.001. Measurements
were done on four individual mice of different ages.
doi:10.1371/journal.pone.0038708.g006
Figure 7. CD3 and CD40 co-stimulation increases production of
some cytokines. Data represented in this figure were part of
experiments done in Figure 6 and can therefore be directly compared
to Figure 6. Cells were sorted as in Figure 6 and were CD3- and CD40-
stimulated in the absence/presence of indicated concentrations of
galectin-9 (gal-9; mg/ml) for 3 days then cytokines were measured. Bar
graphs depict means with SEM. Asterisks denote significant differences
determined by one-way Anova; * – P between 0.01 and 0.05; ** – P
,0.01. Measurements were done on four individual mice of different
ages.
doi:10.1371/journal.pone.0038708.g007
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loCD40
+ T cell population
changed not only the CD40 glycoform profile [17] but also the
glycosylation status of those cells to levels seen in autoimmune
NOD mice [23]. This also disrupted the galectin-9/CD40
interaction. However, this disruption was evident only at the
early timepoints immediately ex-vivo and the interaction then
started to recover at the later timepoints suggesting a reason for
why the in-vitro CD40 induced proliferation of those expanded cells
was not as profound as in the same population from NOD mice.
Therefore, galectin-9 control of CD40 signals in CD4
loCD40
+ T
cells could be one mode of action for galectin-9 to be protective
against diabetes as was demonstrated [28]. However, as several
other cells are affected by galectin-9, including Th1 cells [27,28],
galectin-9 inhibition of T1D must include several modalities.
Stimulation through CD40 has been utilized as an adjuvant in
vaccines [34,35,36]. Therefore our data also indicate that
CD4
loCD40
+ T cells take part in normal immune responses since
agonistic antibody injection of non-autoimmune BALB/c mice
expanded that cell subset. After fourteen days the CD40 induced
expansion of CD4
loCD40
+ T cells in BALB/c mice receded to
normal numbers (data not shown). Given the persistence of CD40
signals in autoimmunity [13] this then suggests that in the
autoimmune setting, mechanisms to control CD4
loCD40
+ T cells
are unavailable or are thwarted by persistent CD40 signals such
that CD4
loCD40
+ T cell expansions, that may have started as part
of a normal immune response, are maintained rather than allowed
to recede.
A very interesting finding is that galectin-9, at sub-lethal
concentrations, causes increased surface expression of CD4, CD3,
TCR and CD5 on NOD CD4
loCD40
+ T cells, essentially de-
cloaking these cells that have long been overlooked precisely
because of their low surface expression of those defining molecules.
The fact that CD4
hi T cells can be activation induced by
CD3+CD28+CD40 stimulation to express lower levels of CD4 on
their surface underscores that CD4 T cells are dynamic.
Functionality of the autoimmune CD4
loCD40
+ T cells is affected
by the availability of CD3 which in turn is affected by galectin-9.
The very different CD4
loCD40
+ T cell cytokine production in
response to CD3 compared to CD40 and the modulation of the
levels produced in the absence/presence of galectin-9 supports this
scenario. Interestingly, CD40 stimulation favors production of IL-
6 and CD3 stimulation favors production of IL-17 and IL-2 while
IFNc is induced to similar levels in response to either treatment.
This suggests that, depending on the microenvironment and on
the availability of signaling molecules on the surface of the cell, an
effector cell can respond very differently in terms of cytokine
output and in terms of whether it survives/proliferates or not.
Therefore it appears that different Th1 phenotypes, including one
that can simultaneously express IFNc and IL-17, can exist in the
same cell population depending on the surface availability and
engagement of the CD40 and CD3 molecules. In addition, the
CD3-induced increase in IL-2 production in the presence of
galectin-9 could mean that if a CD4
loCD40
+ T cell is able to be
stimulated through CD3 instead of CD40 it would be able to
support the function of regulatory T cells which are known to be
dependent on IL-2 [37]. However, the levels of IFNc and IL-2
production were affected by CD3 and CD40 co-stimulation which
further complicates this issue. The expansion of CD4
loCD40
+ T
cells in autoimmunity [12,14,15,16], their often low surface
expression of CD3[14,38] and the constant signaling through
CD40 on those cells [13] indicates that autoimmune mouse
CD4
loCD40
+ T cells may not be able to readily receive CD3
signals. This then would perpetuate the CD40 response and the
CD40 driven cytokine phenotype.
Galectin-9 is known to suppress IL-17 production [39,40].
Contrary to those results, in this manuscript galectin-9 had no
effect on IL-17 production by CD4
loCD40
+ T cells. It is possible
that the different disease models are the reason for this
discrepancy, however, more likely is that the discrepancy is due
to that different cell subsets were studied. CD4
loCD40
+ T cells
studied here are typically gated out by other investigators due to
their low surface expression of CD4. Therefore a direct
comparison of IL-17 levels with other publications may be
inappropriate.
The data presented in this manuscript point to a new area of
exploration in controlling autoimmunity. It is possible that certain
defects in the glycosylation machinery would obligatorily lead to
autoimmunity but in a situation where glycosylation processes are
intact, excessive CD40 signaling could cause immune activating
changes in glycosylation status and then lead to autoimmunity
(Fig. 8). Depending on how persistent and extensive the CD40
signaling is, different gradations of immune activation could occur.
This scenario could explain differences in time of onset and
severity within a given autoimmune disease.
Materials and Methods
Mice
NOD and BALB/c mice were from Taconic (Hudson, NY,
USA) and Jackson Laboratories (Bar Harbor, ME, USA) re-
spectively, and were housed under pathogen free conditions at the
University of Colorado Denver, AAALAC-approved facility and
all experiments were carried out under IACUC-approved protocol
number 55809(03)1E. The NOD mice consistently achieve .90%
diabetes in females by the age of 18 weeks.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
experiments conducted in this study were carried out under
University of Colorado Denver Institutional Animal Care and Use
Committee approved protocol number 55809(03)1E.
Antibodies and reagents
MHCII-, CD8- and CD4-conjugated microbeads for cell-
sorting were purchased from Miltenyi Biotec (Auburn, CA,
USA). CD40 antibodies 1C10 [41] and FGK45 [42] were
produced and biotin or FITC conjugated in house. Isotype
antibodies, Tim-3 antibody (8B.2C12), biotin-conjugated CD3
(145–2C11) and CD28 (37.51) antibodies, fluorochrome conju-
gated antibodies to CD3 (145.2C11; PE), TCR (H57–597; PE–
Cy5), CD5 (53–7.3; FITC), CD8 (53–6.7; PE), and CD28 (37.51;
PE) were purchased from eBioscience, Inc. (San Diego, CA, USA).
Anti-CD4 (H129.19; PE-Cy5) was from BD Pharmingen (San
Diego, CA, USA). P. vulgaris Leukoagglutinin (L-PHA) was from
Vector Laboratories (Burlingame, CA, USA). Recombinant
human galectin-9 (which shares 70% amino acid sequence identity
with mouse galectin-9) was purchased from R&D SystemsH
(Minneapolis, MN, USA). DMEM was from HyClone Laborato-
ries, Inc. (Logan, UT, USA) and fetal calf serum from Gemini Bio
Products (Atlanta, GA, USA). Magnetic beads used in immuno-
precipitations, MyOne
TM tosylactivated DynabeadsH, were from
Invitrogen (Grand Island, NY, USA). Cytokine analysis kit was
from eBioscience, Inc. (San Diego, CA, USA). All other reagents
were from Sigma-AldrichH (St. Louis, MO, USA).
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Splenic CD4
loCD40
+ and CD4
hi T cells from 7 – 13 week old,
female NOD or BALB/c mice were sorted using an autoMACS
TM
(Miltenyi Biotec, Auburn, CA, USA) as previously described [13]
with the exception that directly conjugated CD4-microbeads were
used instead of biotinylated CD4-antibody followed by streptavi-
din-microbeads. This sort results in .90% pure CD4
loCD40
+ cells
and .95% pure CD4
hi cells. Cells were cultured in DMEM
containing 10% fetal calf serum and 50 mM b-mercaptoethanol.
Cells were seeded at either 2610
6 cells per well, in 0.5 ml medium,
in 48-well plates or at 1610
6 cells per well, in 0.1 ml medium, in
96-well plates. Cells were CD40 crosslinked using 10 mg/ml of
biotinylated anti-CD40 antibody (1C10) or CD28 crosslinked
using 5 ug/ml anti-CD28 antibody (37.51) followed by 1 mg/ml of
streptavidin. For CD3 crosslinking, 1.0 mg/ml biotinylated anti-
CD3 antibody (145-2C11) was used followed by 0.1 mg/ml
streptavidin. Experiments using galectin-9 were done at concen-
trations/times indicated in the figure legends.
In-vivo antibody treatments
To stimulate CD40 in-vivo, 10 – 12 week old female BALB/c
mice were injected intraperitoneally with 25 mg each of anti-
CD40 antibodies 1C10 and FGK45. Three days after the
injection, spleens were harvested and cells purified as described
above.
T cell proliferation and death assays
T cell proliferation was measured by CFSE dilution [13].
Apoptotic death rates were measured by intracellular propidium
iodide staining as described [43]. Briefly, cells were fixed in
paraformaldehyde/PBS then permeabilized in saponin/PBS.
Propidium iodide (PI) was added to the fixed/permeabilized
cells and allowed to intercalate with the DNA. Apoptotic cells are
considered those that stain poorly with PI due to the small DNA
size of apoptotic cells. For necrotic death, samples were stained
immediately with PI for 10 minutes, without first fixing and
permeabilizing the cells, to measure any uptake of propidium
iodide due to leaky or damaged cells. In this strategy any strong
staining cell, where PI intercalates with the still intact DNA, is
considered necrotic. The measurements were confirmed by
counting absolute numbers of live versus dead cells in trypan
blue.
Immunoprecipitations and western blots
Sorted and treated cells were lysed in lysis buffer (20 mM Tris-
HCl pH 7.5, 2 mM EDTA, 137 mM NaCl, 0.5% Triton X-100,
1 mg/ml each of leupeptin and aprotinin, 0.2 mM PMSF and
0.4 mM sodium-orthovanadate) and incubated for 10 minutes at
room temperature then lysates were clarified by centrifuging at
16 K6g for 3 minutes. FGK45-conjugated or galectin-9 protein
conjugated magnetic beads (conjugated according to manufac-
turer’s protocol) were immediately added to the lysates and
incubated for 20–30 minutes, rotating at room temperature. A
strong magnet (Invitrogen) was used to wash the beads three times
with lysis buffer then the immunoprecipitated material was eluted
using 0.1 M sodium citrate at pH 3.0.
Western blots were performed as described [13].
Protein sequencing
Protein sequencing was done, by applying LC-LC-MS to
protein bands isolated from polyacrylamide gel separated CD40
immunoprecipitates, at the University of Colorado Cancer Center
Proteomics Core (University of Colorado Denver, Anschutz
Figure 8. Glycosylation and immune status. Cartoon depicting different possibilities for immune activation during normal and disease states.
doi:10.1371/journal.pone.0038708.g008
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University of Colorado Comprehensive Cancer Center Core
Support P20 CA046934–17).
Cytokine analysis
Cells were disrupted by freezing them in the growth medium
then thawing. Debris was pelleted by centrifugation then cytokines
were measured in the supernatant. Cytokine analysis was done
using a mouse Th1/Th2 10plex kit and analysis of cytokine levels
was done using the software provided with the kit.
Flow cytometry
Flow cytometry was done on a FACS Calibur flow cytometer
(BD Biosciences, San Jose, CA, USA) and analysis performed
using FlowJo (Ashland, OR, USA) analysis software.
Data analysis
Data analysis was performed using GraphPad Prism 5 from
GraphPad Software, Inc. (La Jolla, CA, USA). One- or two-way
Anova was used, as appropriate, to determine significance.
Supporting Information
Figure S1 CD40 and CD3 induced cytokine phenotypes
differ. CD4
loCD40
+ T cells were sorted from 7–20 weeks old
female NOD spleens. Cells were either CD40- or CD3-stimulated
in the absence/presence of indicated concentrations of galectin-9
(gal-9; mg/ml) for 3 days then cytokines were measured. Bar
graphs depict means with SEM. Measurements were done on four
individual mice of different ages.
(PDF)
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